Stereotactic Body Radiotherapy Promising for Pancreatic Cancer
The addition of stereotactic body radiotherapy to chemotherapy extended OS among patients with unresectable pancreatic cancer, according to data from a retrospective analysis
Five-year survival rates for patients with pancreatic cancer remain low, at less than 8%. Complete surgical resection extends survival. However, between 80% and 85% of patients present with unresectable disease. Read more . . .
